Kenya has been participating in a small-scale trial of the AstraZeneca vaccine, which requires two doses administered weeks apart.
The vaccine can be stored at what AstraZeneca has called “normal refrigerated conditions,” which is expected to help in parts of the African continent where poor infrastructure will challenge the mass rollout of doses.
Kenya's news came as South Africa on Thursday announced it will begin receiving 1.5 million doses of the AstraZeneca vaccine later this month, the first announced deal for COVID-19 doses in the country with more than 1 million confirmed infections.
A recent surge in infections has eased, and schools reopened this week, but health workers in Kenya have expressed concern about the lack of support as some doctors and others die without being able to afford proper care. Doctors across the country held a brief strike last month over inadequate personal protective equipment and insurance.
While some of Africa's richer countries are now announcing vaccine deals — Morocco last month announced it had ordered 65 million doses from AstraZeneca and China’s Sinopharm — it's not clear how long it will take for COVID-19 vaccines to reach countries on the 54-nation continent without the resources to strike their own agreements.
The head of the Africa Centers for Disease Control and Prevention has expressed concern that the coronavirus could become endemic in parts of Africa if it takes more than two or three years to vaccinate 60% of the continent’s population of some 1.3 billion people.